For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | 0 | 0 | 0 | 0 |
| Research and development | 150,150,000 | 153,458,000 | 89,953,000 | 60,153,000 |
| General and administrative | 13,975,000 | 11,280,000 | 8,608,000 | 14,421,000 |
| Total operating expenses | 164,125,000 | 164,738,000 | 98,561,000 | 74,574,000 |
| Loss from operations | -164,125,000 | -164,738,000 | -98,561,000 | -74,574,000 |
| Realized gain on investments, net | 0 | - | 10,000 | 4,000 |
| Amortization of financing costs | 0 | 0 | 8,000 | 24,000 |
| Interest income, net | 5,800,000 | 7,035,000 | 7,772,000 | 9,033,000 |
| Realized gain on investments, net | - | 41,000 | - | - |
| Total other income, net | 5,800,000 | 7,076,000 | 7,774,000 | 9,013,000 |
| Net loss | -158,325,000 | -157,662,000 | -90,787,000 | -65,561,000 |
| Unrealized loss on securities | -1,250,000 | -10,000 | 540,000 | 26,000 |
| Foreign currency translation gain (loss) | 16,000 | 14,000 | 0 | 24,000 |
| Comprehensive loss | -159,559,000 | -157,658,000 | -90,247,000 | -65,511,000 |
| Basic EPS | -1.37 | -1.381 | -0.81 | -0.58 |
| Diluted EPS | -1.37 | -1.381 | -0.81 | -0.58 |
| Basic Average Shares | 115,568,000 | 114,145,000 | 112,320,000 | 112,134,000 |
| Diluted Average Shares | 115,568,000 | 114,145,000 | 112,320,000 | 112,134,000 |
Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc. (VKTX)